Preventing and Managing Bleeding With Anticoagulation for Atrial Fibrillation
- PMID: 34140102
- PMCID: PMC8091380
- DOI: 10.1016/j.jacc.2021.04.053
Preventing and Managing Bleeding With Anticoagulation for Atrial Fibrillation
Keywords: andexanet alfa; bleeding; direct oral anticoagulants; idarucizumab; reversal agents.
Conflict of interest statement
Funding Support and Author Disclosures Dr. Pokorney has received modest consulting support from Bristol Myers Squibb, Pfizer, Boston Scientific, Medtronic, Janssen Pharmaceuticals, and Zoll; has received modest research support from Gilead, Boston Scientific, Bristol Myers Squibb, Pfizer, and Janssen Pharmaceuticals; and has received significant research support from the U.S. Food and Drug Administration. Dr. Granger has received research and consulting fees from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Bayer, Janssen, Boston Scientific, Apple, AstraZeneca, Novartis, Abbvie, Biomed, CeleCor, GSK, Novartis, Medtronic, Merck, Novo Nordisk, Philips, Rho, and the U.S. Food and Drug Administration.
Comment on
-
Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants.J Am Coll Cardiol. 2021 Jun 22;77(24):2987-3001. doi: 10.1016/j.jacc.2021.04.061. J Am Coll Cardiol. 2021. PMID: 34140101
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
